Combination of preoperative platelet/lymphocyte and neutrophil/lymphocyte rates and tumor-related factors to predict lymph node metastasis in patients with gastric cancer

European Journal of Gastroenterology and Hepatology

Volumn 28, Issue 5, 2016, Pages 493-502

  Pang, Wenyang ^a   Lou, Neng ^a   Jin, Cancan ^a   Hu, Changyuan ^a   Arvine, Chandoo ^a   Zhu, Guangbao ^a   Shen, Xian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Combination; Gastric cancer; Lymph node metastasis; Neutrophil lymphocyte rate; Platelet lymphocyte rate

Indexed keywords

ALBUMIN; CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER PATIENT; CANCER SIZE; CANCER STAGING; FEMALE; HUMAN; HYPOALBUMINEMIA; LYMPH NODE METASTASIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; PLATELET LYMPHOCYTE RATIO; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMACH ADENOCARCINOMA; STOMACH ANTRUM; STOMACH CANCER; THROMBOCYTE COUNT; YOUDEN INDEX; ADENOCARCINOMA; AREA UNDER THE CURVE; BLOOD; CHI SQUARE DISTRIBUTION; DECISION SUPPORT SYSTEM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SECONDARY; STATISTICAL MODEL; STOMACH NEOPLASMS; TUMOR VOLUME;

ADENOCARCINOMA; AGED; AREA UNDER CURVE; CHI-SQUARE DISTRIBUTION; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; LOGISTIC MODELS; LYMPHATIC METASTASIS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; STOMACH NEOPLASMS; TUMOR BURDEN;

EID: 84957614386     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000563     Document Type: Article

References (73)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24:2137-2150.
2. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24:2903-2909.
3. Shang J, Pena AS. Multidisciplinary approach to understand the pathogenesis of gastric cancer. World J Gastroenterol 2005; 11:4131-4139.
4. Bando E, Yonemura Y, Taniguchi K, Fushida S, Fujimura T, Miwa K. Outcome of ratio of lymph node metastasis in gastric carcinoma. Ann Surg Oncol 2002; 9:775-784.
5. Deng J, Zhang R, Pan Y, Wang B, Wu L, Hao X, Liang H. N stages of the seventh edition of TNM classification are the most intensive variables for predictions of the overall survival of gastric cancer patients who underwent limited lymphadenectomy. Tumour Biol 2014; 35: 3269-3281.
6. Schwarz RE. Current status of management of malignant disease: current management of gastric cancer. J Gastrointest Surg 2015; 19:782-788.
7. Newton AD, Datta J, Loaiza-Bonilla A, Karakousis GC, Roses RE. Neoadjuvant therapy for gastric cancer: current evidence and future directions. J Gastrointest Oncol 2015; 6:534-543.
8. Fu T, Bu ZD, Li ZY, Zhang LH, Wu XJ, Wu AW, et al. Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarci-noma: a meta-analysis of randomized clinical trials. BMC Cancer 2015; 15:322.
9. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27:851-856.
10. Kim YW, Kim MJ, Ryu KW, Lim HS, Lee JH, Kong SY, et al. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clin-icopathological and pharmacogenetic predictors for survival. Gastric Cancer 2015. [Epub ahead of print].
11. National comprehensive cancer network guidelines version 3; 2015, gastric cancer. Available at: http://www.nccn.org. [Accessed 23 March 2015].
12. Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer 2009; 12:6-22.
13. Seevaratnam R, Cardoso R, McGregor C, Lourenco L, Mahar A, Sutradhar R, et al. How useful is preoperative imaging for tumor, node, metastasis (TNM) staging of gastric cancer? A meta-analysis. Gastric Cancer 2012; 15 (Suppl 1):S3-S18.
14. Shim CN, Lee SK. Endoscopic submucosal dissection for undifferentiated-type early gastric cancer: do we have enough data to support this? World J Gastroenterol 2014; 20:3938-3949.
15. Huang KH, Lan YT, Fang WL, Chen JH, Lo SS, Li AF, et al. The correlation between miRNA and lymph node metastasis in gastric cancer. Biomed Res Int 2015; 2015:543163.
16. Morita H, Ishikawa Y, Akishima-Fukasawa Y, Ito K, Akasaka Y, Nishimura C, et al. Histopathological predictor for regional lymph node metastasis in gastric cancer. Virchows Arch 2009; 454: 143-151.
17. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883-899.
18. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-867.
19. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-545.
20. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 2013; 39:534-540.
21. Jiang N, Deng JY, Liu Y, Ke B, Liu HG, Liang H. The role of preoperative neutrophil-lymphocyte and platelet-lymphocyte ratio in patients after radical resection for gastric cancer. Biomarkers 2014; 19: 444-451.
22. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013; 88:218-230.
23. Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J, et al. Prognostic value of PLR in various cancers: a meta-analysis. PLoS One 2014; 9:e101119.
24. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011; 14: 101-112.
25. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. Biom J 2005; 47:458-472.
26. Mocellin S, Marchet A, Nitti D. EUS for the staging of gastric cancer: a meta-analysis. Gastrointest Endosc 2011; 73:1122-1134.
27. Badgwell B, Ajani J, Blum M, Ho L, Fournier K, Chiang YJ, et al. Postoperative morbidity and mortality rates are not increased for patients with gastric and gastroesophageal cancer who undergo preoperative chemoradiation therapy. Ann Surg Oncol 2016; 23: 156-162.
28. Shum H, Rajdev L. Multimodality management of resectable gastric cancer: a review. World J Gastrointest Oncol 2014; 6:393-402.
29. Sun Z, Nussbaum DP, Speicher PJ, Czito BG, Tyler DS, Blazer DG 3rd. Neoadjuvant radiation therapy does not increase perioperative morbidity among patients undergoing gastrectomy for gastric cancer. J Surg Oncol 2015; 112:46-50.
30. Leong T, Smithers BM, Michael M, Gebski V, Boussioutas A, Miller D, et al. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer 2015; 15:532.
31. Schirren R, Reim D, Novotny AR. Adjuvant and/or neoadjuvant therapy for gastric cancer? A perspective review. Ther Adv Med Oncol 2015; 7:39-48.
32. Dong S, Yu JR, Zhang Q, Liu XS. Neoadjuvant chemotherapy in controlling lymph node metastasis for locally advanced gastric cancer in a Chinese population. J Chemother 2015. [Epub ahead of print].
33. Wu ZM, Teng RY, Shen JG, Xie SD, Xu CY, Wang LB. Reduced lymph node harvest after neoadjuvant chemotherapy in gastric cancer. J Int Med Res 2011; 39:2086-2095.
34. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010; 28:5210-5218.
35. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Cooperative Group. Br J Cancer 1999; 79:1522-1530.
36. Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004; 22:2069-2077.
37. Degiuli M, Sasako M, Ponti A, Vendrame A, Tomatis M, Mazza C, et al. Randomized clinical trial comparing survival after d1 or d2 gastrectomy for gastric cancer. Br J Surg 2014; 101:23-31.
38. Ma Y, Li YF, Wang T, Pang R, Xue YW, Zhao SP. Identification of proteins associated with lymph node metastasis of gastric cancer. J Cancer Res Clin Oncol 2014; 140:1739-1749.
39. Deng J, Jiao X, Liu H, Wu L, Zhang R, Wang B, et al. Lymph node metastasis is mediated by suppressor of cytokine signaling-3 in gastric cancer. Tumour Biol 2013; 34:3627-3636.
40. Shimada H, Takiguchi N, Kainuma O, Soda H, Ikeda A, Cho A, et al. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 2010; 13:170-176.
41. Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol 2004; 39:687-699.
42. Rashid F, Waraich N, Bhatti I, Saha S, Khan RN, Ahmed J, et al. A pre-operative elevated neutrophil: Lymphocyte ratio does not predict survival from oesophageal cancer resection. World J Surg Oncol 2010; 8:1.
43. Zhang Y, Zhu Z, Sun Z, Wang Z, Zheng X, Xu H. Preoperative predicting score of lymph node metastasis for gastric cancer. Tumour Biol 2014; 35:10437-10442.
44. Jin EH, Lee DH, Jung SA, Shim KN, Seo JY, Kim N, et al. Clinicopathologic factors and molecular markers related to lymph node metastasis in early gastric cancer. World J Gastroenterol 2015; 21:571-577.
45. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009; 12:223-226.
46. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007; 121:2373-2380.
47. Ramadori G, Van Damme J, Rieder H, Meyer zum Büschenfelde KH. Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor-alpha. Eur J Immunol 1988; 18:1259-1264.
48. Kim DK, Oh SY, Kwon HC, Lee S, Kwon KA, Kim BG, et al. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 2009; 9:155.
49. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002; 9:287-291.
50. Kim EY, Lee JW, Yoo HM, Park CH, Song KY. The platelet-to-lymphocyte ratio versus neutrophil-to-lymphocyte ratio: which is better as a prognostic factor in gastric cancer? Ann Surg Oncol 2015; 22:4363-4370.
51. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immu-nosurveillance and immunoediting. Immunity 2004; 21:137-148.
52. Ubukata H, Motohashi G, Tabuchi T, Nagata H, Konishi S, Tabuchi T. Evaluations of interferon-γ/interleukin-4 ratio and neutrophil/lymphocyte ratio as prognostic indicators in gastric cancer patients. J Surg Oncol 2010; 102:742-747.
53. Liu H, Tabuchi T, Takemura A, Kasuga T, Motohashi G, Hiraishi K, et al. The granulocyte/lymphocyte ratio as an independent predictor of tumour growth, metastasis and progression: its clinical applications. Mol Med Rep 2008; 1:699-704.
54. Liu H, Ubukata H, Tabuchi T, Takemura A, Motohashi G, Nishimura M, et al. It is possible that tumour-infiltrating granulocytes promote tumour progression. Oncol Rep 2009; 22:29-33.
55. Petrie HT, Klassen LW, Kay HD. Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol 1985; 134:230-234.
56. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007; 73:215-220.
57. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003; 6:283-287.
58. Noh H, Eomm M, Han A. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer 2013; 16:55-59.
59. Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A. Are neutrophil/lym-phocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev 2013; 14:5237-5242.
60. Lee S, Oh SY, Kim SH, Lee JH, Kim MC, Kim KH, Kim HJ. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer 2013; 13:350.
61. Jain S, Harris J, Ware J. Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol 2010; 30:2362-2367.
62. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost 2011; 9:237-249.
63. Liu HB, Gu XL, Ma XQ, Lv TF, Wu Y, Xiao YY, et al. Preoperative platelet count in predicting lymph node metastasis and prognosis in patients with non-small cell lung cancer. Neoplasma 2013; 60: 203-208.
64. Lin MS, Huang JX, Zhu J, Shen HZ. Elevation of platelet count in patients with colorectal cancer predicts tendency to metastases and poor prognosis. Hepatogastroenterology 2012; 59:1687-1690.
65. Huang C, Yue J, Li Z, Li N, Zhao J, Qi D. Usefulness of the neutrophil-to-lymphocyte ratio in predicting lymph node metastasis in patients with non-small cell lung cancer. Tumour Biol 2015; 36:7581-7589.
66. Ertas IE, Gungorduk K, Akman L, Ozdemir A, Terek MC, Ozsaran A, et al. Can preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios be used as predictive markers for lymph node metastasis in squamous cell carcinoma of the vulva? Eur J Obstet Gynecol Reprod Biol 2013; 171:138-142.
67. Suh DH, Kim HS, Chung HH, Kim JW, Park NH, Song YS, Kang SB. Pre-operative systemic inflammatory response markers in predicting lymph node metastasis in endometrioid endometrial adenocarcinoma. Eur J Obstet Gynecol Reprod Biol 2012; 162:206-210.
68. Aliustaoglu M, Bilici A, Ustaalioglu BB, Konya V, Gucun M, Seker M, Gumus M. The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment. Med Oncol 2010; 27:1060-1065.
69. Cho IR, Park JC, Park CH, Jo JH, Lee HJ, Kim S, et al. Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict che-motherapeutic response and survival outcomes in metastatic advanced gastric cancer. Gastric Cancer 2014; 17:703-710.
70. Li W, Ye F, Wang D, Sun X, Tong W, Lian G, et al. Protein predictive signatures for lymph node metastasis of gastric cancer. Int J Cancer 2013; 132:1851-1859.
71. Shida A, Fujioka S, Kawamura M, Takahashi N, Ishibashi Y, Nakada K, et al. Prediction of lymph node metastasis in patients with submucosa-invading early gastric cancer. Anticancer Res 2014; 34:4471-4474.
72. Feng XY, Wang W, Luo GY, Wu J, Zhou ZW, Li W, et al. Comparison of endoscopic ultrasonography and multislice spiral computed tomography for the preoperative staging of gastric cancer-results of a single institution study of 610 Chinese patients. PLoS One 2013; 8: e78846.
73. Wang Q, Yang Y, Zhang YP, Zou Z, Qian X, Liu B, et al. Prognostic value of carbohydrate tumor markers and inflammation-based markers in metastatic or recurrent gastric cancer. Med Oncol 2014; 31:289.